Cargando…

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo

Proteasome-addicted neoplastic malignancies present a considerable refractory and relapsed phenotype with patients exhibiting drug resistance and high mortality rates. To counter this global problem, novel proteasome-based therapies are being developed. In the current study, we extensively character...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tandon, Vasudha, Vala, Ruturajsinh M., Chen, Albert, Sah, Robert L., Patel, Hitendra M., Pirrung, Michael C., Banerjee, Sourav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2022
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837819/ https://www.ncbi.nlm.nih.gov/pubmed/35088066 http://dx.doi.org/10.1042/BSR20212721

Ejemplares similares

Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and in vitro anti-glioma activity
por: Vala, Ruturajsinh M., et al.
Publicado: (2022)

Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins
por: Nathan, James A., et al.
Publicado: (2013)

The Molecular Mechanisms Governing the Assembly of the Immuno- and Thymoproteasomes in the Presence of Constitutive Proteasomes
por: Watanabe, Ayaka, et al.
Publicado: (2022)

Versatile Synthetic Platform for 1,2,3-Triazole Chemistry
por: Vala, Disha P., et al.
Publicado: (2022)

Pyridine-2-carboxylic acid as an effectual catalyst for rapid multi-component synthesis of pyrazolo[3,4-b]quinolinones
por: Sharma, Mayank G., et al.
Publicado: (2020)

Importance of Hybrid Catalysts toward the Synthesis of 5H-Pyrano[2,3-d]pyrimidine-2-ones/2,4-diones (Thiones)
por: Parmar, Mehul P., et al.
Publicado: (2023)

Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes
por: Villoutreix, Bruno O., et al.
Publicado: (2017)

Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome
por: Qin, Xianyun, et al.
Publicado: (2021)

One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3,5-dicarbonitriles enabling anti-cancer bioactivity
por: Nicely, Lynden G., et al.
Publicado: (2022)

Impact of an aryl bulky group on a one-pot reaction of aldehyde with malononitrile and N-substituted 2-cyanoacetamide
por: Vala, Ruturajsinh M., et al.
Publicado: (2019)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Tir
Publicado: (1965)

(Immuno)proteasomes as therapeutic target in acute leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2017)

Tir & lir /
por: Redonnet, Marie
Publicado: (1988)

Dysregulation of the (immuno)proteasome pathway in malformations of cortical development
por: van Scheppingen, J., et al.
Publicado: (2016)

Dual inhibition of HSF1 and DYRK2 impedes cancer progression
por: Tandon, Vasudha, et al.
Publicado: (2023)

Dissecting the role of the Tir:Nck and Tir:IRTKS/IRSp53 signalling pathways in vivo
por: Crepin, Valérie F, et al.
Publicado: (2010)

Correction to: The Role of TIR-NBS and TIR-X Proteins in Plant Basal Defense Responses
Publicado: (2022)

Synthesis, crystal structure and in silico studies of novel 2,4-dimethoxy-tetrahydropyrimido[4,5-b]quinolin-6(7H)-ones
por: Patel, Subham G., et al.
Publicado: (2022)

Catalyst-Free, Room-Temperature Accessible Regioselective Synthesis of Spiroquinolines and Their Antioxidant Study
por: Patel, Paras J., et al.
Publicado: (2022)

A Sentinel in the Crosstalk Between the Nervous and Immune System: The (Immuno)-Proteasome
por: Limanaqi, Fiona, et al.
Publicado: (2019)

Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors
por: Schiffrer, Eva Shannon, et al.
Publicado: (2021)

Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome
por: Diez-Rivero, Carmen M, et al.
Publicado: (2010)

Differential requirement of TIR enzymatic activities in TIR-type immune receptor SNC1-mediated immunity
por: Tian, Lei, et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Structural Evolution of TIR-Domain Signalosomes
por: Nimma, Surekha, et al.
Publicado: (2021)

High resolution mapping of trypanosomosis resistance loci Tir2 and Tir3 using F12 advanced intercross lines with major locus Tir1 fixed for the susceptible allele
por: Nganga, Joseph K, et al.
Publicado: (2010)

Quantitative time-resolved analysis reveals intricate, differential regulation of standard- and immuno-proteasomes
por: Liepe, Juliane, et al.
Publicado: (2015)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Microwave-assisted multicomponent synthesis of antiproliferative 2,4-dimethoxy-tetrahydropyrimido[4,5-b]quinolin-6(7H)-ones
por: Patel, Subham G., et al.
Publicado: (2022)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2
por: Banerjee, Sourav, et al.
Publicado: (2018)

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression
por: Banerjee, Sourav, et al.
Publicado: (2019)

TIR-1/SARM1 inhibits axon regeneration and promotes axon degeneration
por: Czech, Victoria L, et al.
Publicado: (2023)

Supersymétrie : Le LEP règle le tir
Publicado: (1991)

Combining TIR and FRET in Molecular Test Systems
por: Schneckenburger, Herbert, et al.
Publicado: (2019)

Broader functions of TIR domains in Arabidopsis immunity
por: Jacob, Pierre, et al.
Publicado: (2023)

Emerging roles of DYRK2 in cancer
por: Tandon, Vasudha, et al.
Publicado: (2021)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
por: Kollár, Levente, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_48472645hlsqsbvblq6iqbufs6